<DOC>
	<DOC>NCT01516476</DOC>
	<brief_summary>This randomized, double-blind, placebo-controlled, multi-center study will evaluate the efficacy and safety of RO6807952 in patients with diabetes mellitus type 2 inadequately controlled with metformin alone. Patients will be randomized to receive doses of RO6807952, placebo, or liraglutide. The anticipated time on study treatment is 12 weeks.</brief_summary>
	<brief_title>Study of RO6807952 in Patients With Diabetes Mellitus Type 2</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Adult patients &gt;/= 18 and &lt;/=70 years of age Diagnosis of diabetes mellitus, type 2 for at least 3 months Treated with a stable dose of metformin Hemoglobin A1c &gt;/=7.0% and &lt;/=10.5% at screening Fasting plasma glucose &lt;/=240 mg/dL at screening Body mass index &gt;/=27 kg/m2 and &lt;/=42 kg/m2 at screening Willing and able to maintain existing diet and exercise habits throughout the study Cpeptide &gt;1.5 ng/mL at screening History of significant liver or kidney disease History of uncontrolled hypertension History of significant cardiovascular disease History of significant diabetic complications History of significant gastrointestinal conditions History of weight loss surgery or procedures involving the gastrointestinal tract History of chronic or acute pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>